Loading…
Solid Biosciences Inc. is projected to rise to $9.22 by 2027, a +14% move from its current price of $8.06. SLDB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $7.79 | $8.06 | $8.33 | 0.00% |
| Aug 3 | $7.69 | $8.06 | $8.45 | +0.01% |
| Aug 4 | $7.61 | $8.06 | $8.54 | +0.01% |
| Aug 5 | $7.54 | $8.06 | $8.62 | +0.01% |
| Aug 6 | $7.48 | $8.06 | $8.69 | +0.01% |
| Aug 7 | $7.43 | $8.06 | $8.75 | +0.02% |
| Aug 8 | $7.38 | $8.06 | $8.81 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.38 | $8.06 | $8.81 | +0.02% |
| Week 2 | $7.11 | $8.06 | $9.14 | +0.04% |
| Week 3 | $6.92 | $8.06 | $9.40 | +0.05% |
| Week 4 | $6.75 | $8.07 | $9.63 | +0.07% |
| Week 5 | $6.62 | $8.07 | $9.84 | +0.09% |
| Week 6 | $6.49 | $8.07 | $10.03 | +0.11% |
| Week 7 | $6.38 | $8.07 | $10.20 | +0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for Friedreich's ataxia that is in phase 1b clinical trial.
In addition, SGT-501 for catecholaminergic polymorphic ventricular tachycardia is in preclinical phase; SGT-601 for TNNT2-mediated dilated cardiomyopathy is in preclinical phase; SGT-401 for BAG3-mediated dilated cardiomyopathy is in preclinical phase; and SGT-701 for a rare inherited disease characterized by RBM20 mutations is in discovery phase. The company is also involved in platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.
The company has collaboration and license agreements with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Solid Biosciences (SLDB) is a clinical-stage biotech focused on therapies for neuromuscular and cardiac diseases, with a portfolio that includes SGT-003 in Phase 1/2 and several other programs at various stages. The stock is currently trading with a market capitalization of $832.88M and a liquidity and price setup reflected by its current price of $8.10.
The asset sits at a market-cap rank of 5426 with a 30-day price range of $6.36 to $10.32, and a current price that aligns near its moving averages. The SMA50 is $8.16 and the SMA200 is $6.72, with near-term support at $6.57 and resistance at $11.15. These nearby technical levels frame a structure that supports a mixed near-term view but a long-run bullish forecast.
A major floor 29.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.9% away) — a key level to hold.
The nearest ceiling, 38.3% above — a clean break opens room to run.
A major ceiling 53.0% above — clearing it would confirm fresh momentum.
Key SLDB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLDB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.09 | Sell | $8.15 | Sell |
| MA 10 | $8.13 | Sell | $8.32 | Sell |
| MA 20 | $9.14 | Sell | $8.60 | Sell |
| MA 50 | $8.29 | Sell | $8.43 | Sell |
| MA 100 | $7.91 | Buy | $7.90 | Buy |
| MA 200 | $6.80 | Buy | $7.17 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.91 | Neutral |
| Stoch RSI (14) | 31.11 | Neutral |
| CCI (20) | -67.68 | Neutral |
| Williams %R (14) | -87.22 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -16.22 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 12.78 | Buy |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | -0.88 | Sell |
| Ultimate (7,14,28) | 41.05 | Neutral |
| Momentum (10) | -0.66 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 8.21 | Sell |
| ADX (14) | 22.31 | Sell |
| ATR (14) | 0.27 | Info |
The 30-day picture shows RSI(14) at 40, which leaves room for movement in either direction. The moving-average setup is constructive, with the SMA50 at $8.16 above the SMA200 at $6.72, suggesting a bullish tilt on a short horizon.
Key levels to watch include support at $6.57 and resistance at $11.15, and the 30-day range spans from $6.36 to $10.32. The current price of $8.10 sits near the mid-point of this range and near the SMA50, implying potential for near-term action within the established bounds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.16 | $8.06 | $10.27 | 0% | Neutral | |
| $7.21 | $9.22 | $12.58 | +14% | Neutral | |
| $9.48 | $12.57 | $17.92 | +56% | Bullish | |
| $10.79 | $14.74 | $21.75 | +83% | Bullish | |
| $10.10 | $14.17 | $21.53 | +76% | Bullish | |
| $10.97 | $15.76 | $24.55 | +96% | Bullish | |
| $11.59 | $17.03 | $27.13 | +111% | Bullish | |
| $11.97 | $17.96 | $29.19 | +123% | Bullish | |
| $15.71 | $24.05 | $39.81 | +198% | Bullish | |
| $16.64 | $25.97 | $43.75 | +222% | Bullish | |
| $24.05 | $41.02 | $74.19 | +409% | Bullish | |
| $32.83 | $65.56 | $131.37 | +713% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.16 | $8.06 | $10.00 | +0.00% |
| September 2026 | $6.76 | $8.05 | $9.90 | -0.13% |
| October 2026 | $6.73 | $8.08 | $10.06 | +0.36% |
| November 2026 | $6.86 | $8.29 | $10.43 | +2.63% |
| December 2026 | $6.64 | $8.08 | $10.27 | -2.51% |
Click any year to see its month-by-month SLDB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect SLDB to range from $5.16 to $10.27 through 2026. The $8.06 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The SLDB price prediction for 2027 points to an average of $9.22 (low $7.21, high $12.58) — a potential gain of +14% on today's $8.06. A consolidation phase looks the most probable path here.
In 2028, SLDB is projected to trade between $9.48 and $17.92, averaging $12.57 — a potential gain of +56% from today's $8.06. That is up +36% on the projected 2027 average. Momentum favours further upside here.
Solid Biosciences Inc.'s 2029 outlook centres on $14.74, within a $10.79 to $21.75 range. That is up +17% on the projected 2028 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, SLDB could reach as high as $21.53, with a base case around $14.17 and support toward $10.10 — roughly +76% from $8.06. Momentum favours further upside here.
Expect SLDB to range from $10.97 to $24.55 through 2031. The $15.76 average target implies a +96% move from current prices. That is up +11% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The SLDB price prediction for 2032 points to an average of $17.03 (low $11.59, high $27.13) — a potential gain of +111% on today's $8.06. Momentum favours further upside here.
In 2033, SLDB is projected to trade between $11.97 and $29.19, averaging $17.96 — a potential gain of +123% from today's $8.06. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Solid Biosciences Inc.'s 2034 outlook centres on $24.05, within a $15.71 to $39.81 range. That is up +34% on the projected 2033 average. That marks a +198% change versus current levels. Momentum favours further upside here.
By 2035, SLDB could reach as high as $43.75, with a base case around $25.97 and support toward $16.64 — roughly +222% from $8.06. Buyers look set to stay in control over this stretch.
Expect SLDB to range from $24.05 to $74.19 through 2040. The $41.02 average target implies a +409% move from current prices. That is up +58% on the projected 2035 average. Momentum favours further upside here.
The SLDB price prediction for 2050 points to an average of $65.56 (low $32.83, high $131.37) — a potential gain of +713% on today's $8.06. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLDB today (≈ 124.069479 SLDB) could be worth
$8,133.41
+$7,133.41 (+713%) by 2050 · US Dollar
Based on the average projected SLDB price of $65.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLDBwould be worth at today's price.
$1,000 invested in SLDB on Jul 31, 2025 (≈ 146.198827 SLDB) would be worth
$1,178.36
+$178.36 (+17.8%) today · 1.18× · US Dollar
Based on a SLDB entry price of $6.84 vs. today's $8.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.83 | $1,029.37 | +2.9% |
| 1 month ago | $10.2 | $790.2 | -21.0% |
| 3 months ago | $7.13 | $1,130.43 | +13.0% |
| 6 months ago | $6.43 | $1,253.5 | +25.3% |
| 1 year ago | $6.84 | $1,178.36 | +17.8% |
| All time (5.0y) ago | $41.55 | $193.98 | -80.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLDB forecast.
Our base-case forecast reaches $16.00 around 2032.
Implied market cap at $16.00: $1.58B
The year-by-year forecast shows a path of gradual upside with notable accelerations in later years. For 2026 the min, avg, and max are $5.16, $8.10, and $10.20 respectively, with a 0% ROI and Neutral sentiment.
From 2027 onward, the forecasts imply rising averages and higher ROIs: 2027 avg $9.37 (ROI 15.6%, Neutral), 2028 avg $12.79 (57.8%, Bullish), 2029 avg $14.72 (81.7%, Bullish), and 2030 avg $14.24 (75.8%, Bullish). The momentum continues through 2031–2033 with avg prices of $15.75, $16.73, and $17.81 and ROI of 94.5%, 106.5%, and 119.9% respectively.
The trajectory remains bullish into the mid-2030s with 2034 avg $24.12 (197.8%), 2035 avg $25.83 (218.9%). By 2040 the avg price is forecast at $41.24 with a 409.1% ROI, and by 2050 the avg price is $62.78 with a 675% ROI. The sentiment shifts to Bullish across these later years. These are estimates, not guarantees, and actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows min $9.93, avg $14.24, max $22.12 with ROI 75.8% and sentiment Bullish.
Forecasts show Neutral in 2026 with an avg price of $8.10, then rising to Bullish sentiment with increasing ROIs, reaching 675% by 2050. These are estimates, not guarantees.
The 2040 max is $77.13 and the 2050 max is $130.84, so a $100 level is within the 2050 outlook.
Current price is $8.10 and market cap is $832.88M.
RSI(14) is 40; the SMA50 is $8.16 and the SMA200 is $6.72. Support is at $6.57 and resistance at $11.15; the 30-day range is $6.36 to $10.32.
Solid Biosciences Inc. Community Discussion
0Share your Solid Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.